{"schema_version":"secwatch.filing_event.v1","accession":"0000944809-23-000010","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.670198+00:00","generated_at":"2026-06-19T03:54:10.326459+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M","bullets":["Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.","Diagnostics revenue $139.4M (down from $362.8M) due to COVID-19 testing decline; BioReference processed 0.1M PCR tests vs 2.7M.","Pharmaceuticals revenue $37.9M (up from $35.3M) driven by RAYALDEE ($9.1M) and IP transfer ($8.1M); NGENLA sales underway in 15 countries.","Operating loss $55.3M vs $63.1M; cash $153.2M as of Dec 31, 2022.","BioReference implementing cost-cutting initiatives to return to profitability after COVID-19 testing decline."],"urls":{"canonical":"https://secwatch.observer/filing/0000944809-23-000010","json":"https://secwatch.observer/filing/0000944809-23-000010.json","markdown":"https://secwatch.observer/filing/0000944809-23-000010.md","text":"https://secwatch.observer/filing/0000944809-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/0000944809-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/opk-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:54:10.326459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}